ClinicalTrials.gg
Drug

Methylprednisolone clinical trials

Also written Medrol.

Includes 33 studies of Methylprednisolone Acetate and 33 studies of Methylprednisolone Hemisuccinate.

studies test it
405
open now
86
in phase 3
108
first study started
1991

How each study uses Methylprednisolone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Methylprednisolone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
24 Oct 1957 · MEDROL · NDA 011153 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Methylprednisolone
228
Solu-Medrol
40
Depo-Medrol
15
Solumedrol
12
Methylprednisolone (Corticosteroid)
6

Brand

Medrol
25

Other names

6-methyl-prednisolone
1

Studies by the year they started

404 studies that test it; most in 2021 (32)

Studies that test Methylprednisolone, by start year
YearStudies
19911
19931
19941
19953
19972
19982
19992
20003
20012
20025
200310
20046
200515
20063
20078
200812
200917
201014
20117
201219
201312
201415
201524
201615
201713
201816
201920
202029
202132
202219
202316
202415
202521
202624

Who runs them

Industry 23 · Other 382

Rigshospitalet, Denmark (9) · Assiut University (7) · M.D. Anderson Cancer Center (6) · Northwestern University (6) · Assistance Publique - Hôpitaux de Paris (6) · Rush University Medical Center (5) · Emory University (4) · Mayo Clinic (4)

Often tested with

Tested in the same studies.

Cyclophosphamide (29) · Prednisone (24) · Dexamethasone (22) · Rituximab (17) · Antilymphocyte Serum (16) · Cytarabine (13) · Prednisolone (12) · Etoposide (12)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 3 phase 3 studies under way

Methylprednisolone is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 22, 3 in phase 3

Studies that test Methylprednisolone, phase 3 first.

Studies

Open first, then newest update. How each study uses Methylprednisolone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 405

See all 405 studies that test Methylprednisolone →

Given beside what is tested · 197 — Methylprednisolone is usual care or a partner of the new treatment

Showing 20 of 197.

As the comparator · 66 — what is tested is compared with Methylprednisolone

Showing 20 of 66.

Codes

What other systems call Methylprednisolone · ClinicalTrials.gg INT007822

  • MeSH (NLM) D008775MethylprednisoloneConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) X4W7ZR7023METHYLPREDNISOLONEConfirmed FDA, NLM, Wikidata
  • RxNorm 6902Confirmed FDA, Wikidata
  • Wikidata Q417222methylprednisoloneConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C647MethylprednisoloneOne source FDA
  • DrugBank DB00959One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.